Market Research Industry Reports

Diarrhea - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Diarrhea - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 8, 6, 1, 17 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 5
Diarrhea - Overview 6
Diarrhea - Therapeutics Development 7
Diarrhea - Therapeutics Assessment 16
Diarrhea - Companies Involved in Therapeutics Development 25
Diarrhea - Drug Profiles 39
Diarrhea - Dormant Projects 132
Diarrhea - Discontinued Products 135
Diarrhea - Product Development Milestones 136
Appendix 146

List Of Tables

List of Tables
Number of Products under Development for Diarrhea, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Diarrhea - Pipeline by Aegis Therapeutics LLC, H2 2018
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2018
Diarrhea - Pipeline by Albireo Pharma Inc, H2 2018
Diarrhea - Pipeline by Allergan Plc, H2 2018
Diarrhea - Pipeline by Ardelyx Inc, H2 2018
Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2018
Diarrhea - Pipeline by Bharat Biotech Ltd, H2 2018
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2018
Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2018
Diarrhea - Pipeline by Ferring International Center SA, H2 2018
Diarrhea - Pipeline by GP Pharm SA, H2 2018
Diarrhea - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018
Diarrhea - Pipeline by Metacrine Inc, H2 2018
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2018
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2018
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2018
Diarrhea - Pipeline by Novartis AG, H2 2018
Diarrhea - Pipeline by Pfizer Inc, H2 2018
Diarrhea - Pipeline by Prokarium Ltd, H2 2018
Diarrhea - Pipeline by Protagonist Therapeutics Inc, H2 2018
Diarrhea - Pipeline by RaQualia Pharma Inc, H2 2018
Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2018
Diarrhea - Pipeline by RxBio Inc, H2 2018
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2018
Diarrhea - Pipeline by Sublimity Therapeutics Ltd, H2 2018
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2018
Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2018
Diarrhea - Pipeline by Syntiron LLC, H2 2018
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2018
Diarrhea - Pipeline by Zealand Pharma AS, H2 2018
Diarrhea - Dormant Projects, H2 2018
Diarrhea - Dormant Projects, H2 2018 (Contd..1), H2 2018
Diarrhea - Dormant Projects, H2 2018 (Contd..2), H2 2018
Diarrhea - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Diarrhea, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline

USD 2000View Report

Diarrhea - Pipeline Review, H2 2018

Diarrhea - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.Diarrhea

USD 2000View Report

Parkinsons Disease - Pipeline Review, H2 2017

Parkinsons Disease - Pipeline Review, H2 2017Latest Pharmaceutical and Healthcare disease pipeline guide Parkinsons Disease - Pipeline Review, H2 2017, provides an overview of the Parkinsons Disease (Central Nervous System)

USD 2500View Report

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jul 2018
No. of Pages :153
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube